These pharmacogenomic interactions may also impact response to IBD therapies, as rs1077773 was one of 12 genetic markers that predict durable response to anti-TNF therapy in UC patients.5 Furthermore, AHR is the target for the herbal extract Indigo naturalis, which is currently being explored in combination with curcumin as a therapeutic agent for UC with promising results.10 Thus, individual genetic variation impacting the AHR pathway may be important to consider in therapy selection, paving the way towards personalized medicine in IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.